IDEXX Laboratories, Inc. has integrated the SDMA kidney biomarker into its Catalyst CLIP chemistry profiles to enable earlier detection of kidney disease in pets [1].
This integration allows veterinarians to identify kidney injury before functional changes occur. By including this biomarker in the most common point-of-care test panels, the company aims to improve patient outcomes through a more comprehensive renal evaluation during routine checks [3].
The SDMA biomarker is now part of the chemistry profiles used in the Catalyst system. This move expands the veterinary industry's renal testing portfolio by embedding a specialized detector into a standard diagnostic tool [3].
According to company reports, the announcement of this integration occurred on May 19, 2023 [1]. Other records indicate the formal press release was issued from Westbrook, Maine, on June 15, 2023 [2].
Veterinarians use these chemistry profiles to monitor the health of animals. The addition of SDMA provides a tool to detect kidney dysfunction earlier than traditional methods, allowing for intervention before the disease progresses to a more advanced stage [3].
IDEXX said the goal is to provide a complete kidney function evaluation within the routine chemistry panels that clinics already utilize [3]. This approach reduces the need for separate, specialized tests to screen for early-stage renal failure.
“IDEXX Laboratories, Inc. has integrated the SDMA kidney biomarker into its Catalyst CLIP chemistry profiles”
The integration of SDMA into routine chemistry profiles shifts kidney screening from a reactive process to a proactive one. By making a specialized biomarker part of a standard test panel, IDEXX lowers the barrier for early diagnosis, potentially increasing the volume of pets diagnosed with early-stage renal disease who would have otherwise remained undetected until symptoms appeared.
